Efficacy and safety of first-line EGFR-TKI combined with chemotherapy versus EGFR-TKI monotherapy in patients with EGFR-mutant non-small cell lung cancer and liver metastases: A propensity score–matched analysis
First-line EGFR-TKI plus chemotherapy significantly improved PFS and disease control without added toxicity, suggesting a promising therapeutic strategy for EGFR-mutant NSCLC with LM.
Authors
- G. Wang
- Xu He (ORCID: https://orcid.org/0000-0002-2593-9861)
- Jian Wen
- Zhou Long
- Xuemei Wu
- Jia Chen
- Wen Zhang
- Dongfan Ye
Institutions
- Army Medical University (CN)
- Xinqiao Hospital (CN)
Publication Details
- Journal
- Cancer Treatment and Research Communications
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1016/j.ctarc.2026.101108
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00